




Name	Theodore W. Laetsch, MD	
Current Position	Associate Professor, Pediatrics Children's Hospital of Philadelphia / University of Pennsylvania	
Country	United States	
Major Field	Pediatric Oncology	

Educational Background

University of Arizona, Tucson, BS (honors)	05/2001	Biosystems Engineering
University of California, San Francisco, MD	06/2005	Medicine
University of Colorado	06/2008	Pediatric Residency
University of Colorado	06/2009	Chief Residency
Children's Hospital of Philadelphia	06/2012	Heme/Onc Fellowship

Professional Experience

2012-2013 Instructor, Pediatric Oncology, Children's Hospital of Philadelphia, University of Pennsylvania
 2013-2018 Assistant Professor, Pediatric Hematology/Oncology, University of Texas Southwestern
 2018-2020 Associate Professor, Pediatric Hematology/Oncology, University of Texas Southwestern
 2020-present Associate Professor of Pediatrics at the Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine

Other Experience and Professional Memberships

2021-present	Member, American Thyroid Association
2020-present	Member, COG Combination Agent Prioritization and Selection Committee
2019-present	Chair, Rare Tumors Committee, Children's Oncology Group
2016-present	Member, American Society of Hematology (ASH)
2016-present	Member, COG NCI Pediatric MATCH Leadership Committee
2016-present	Member, International Society of Paediatric Oncology (SIOP)
2015-present	Member, Pediatric MATCH Target and Agent Prioritization Committee
2010-present	Member, American Society of Clinical Oncology
2010-present	Member, American Association for Cancer Research
2009-present	Member, American Society of Pediatric Hematology/Oncology
2009-present	Member, Children's Oncology Group



Main Scientific Publications

1. SL Maude, **TW Laetsch**, J Buechner, et al. Tisagenlecleucel in Children and Young Adults with B Lymphoblastic Leukemia. *New England Journal of Medicine*. 2018 Feb 1; 378:439-448 PMID: 29385370 PMID: 29385370 PMCID: PMC5996391
2. **TW Laetsch**, SL Maude, MC Milone, et al. False-Positive Results Following Lentiviral-Based Tisagenlecleucel Therapy with Select HIV-1 NAT Methods. *Blood*. 2018; 131(23):2596-2598. PMID: 29669777 PMCID: PMC6003382
3. **TW Laetsch**, GD Myers, A Baruchel, AC Dietz, MA Pulsipher, H Bittencourt, J Buechner, B De Moerloose, KL Davis, E Nemecek, T Driscoll, F Mechinaud, N Boissel, S Rives, P Bader, C Peters, HS Sabnis, SA Grupp, GA Yanik, H Hiramatsu, HE Stefanski, L Rasouliyan, L Yi, S Shah, J Zhang, AC Harris. Patient-reported Quality of Life After Tisagenlecleucel Infusion in Children and Young Adults with Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia: A Global, Multicentre, Single-arm, Phase 2 Trial. *The Lancet Oncology*. 2019 Dec;20(12):1710-1718. PMID: 31606419 PMCID: PMC7480957
4. Schultz LM, Baggott C, Prabhu S, Pacenta HL, Phillips CL, Rossoff J, Stefanski HE, Talano JA, Moskop A, Margossian SP, Verneris MR, Myers GD, Karras NA, Brown PA, Qayed M, Hermiston M, Satwani P, Krupski C, Keating AK, Wilcox R, Rabik CA, Fabrizio VA, Rouce RH, Chinnabhandar V, Kunicki M, Barsan VV, Goksenin AY, Li Y, Mavroukakis S, Egeler E, Curran KJ, Mackall CL, **Laetsch TW**. Disease Burden Affects Outcomes in Pediatric and Young Adult B-Cell Lymphoblastic Leukemia After Commercial Tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium Report. *J Clin Oncol*. 2021 Dec 9;JCO2003585. doi: 10.1200/JCO.20.03585. Epub ahead of print. PMID: 34882493.
5. **TW Laetsch***, SG DuBois*, R Nagasubramanian, B Turpin, L Mascarenhas, N Federman, M Reynolds, S Smith, S Cruickshank, MC Cox, A Pappo, DS Hawkins. Larotrectinib (LOXO-101) for Pediatric Solid Tumors Harboring NTRK Gene Fusions. *Lancet Oncology*. 2018 Mar 29. PMID: 29606586 PMCID: PMC5949072
6. A. Drilon*, **T.W. Laetsch* (contributed equally)**, S. Kummar, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. *New England Journal of Medicine*. 2018 Feb 22; 378 PMID: 29466156 PMCID: PMC5857389
7. Rudzinski ER, Hechtman J, Roy-Chowdhuri S, Rudolph M, Lockwood CM, Silvertown J, Wierzbinska J, Shen K, Norenberg R, Nogai H, Hong DS, Drilon A, **Laetsch TW**. Diagnostic testing approaches for the identification of patients with TRK fusion cancer prior to enrollment in clinical trials investigating larotrectinib. *Cancer Genet*. 2022 Jan;260-261:46-52. doi: 10.1016/j.cancergen.2021.11.006. Epub 2021 Dec 5. PMID: 34929613.
8. **Laetsch TW**, DuBois SG, Bender JG, Macy ME, Moreno L. Opportunities and Challenges in Drug Development for Pediatric Cancers. *Cancer Discov*. 2021 Mar;11(3):545-559. doi: 10.1158/2159-8290.CD-20-0779. Epub 2020 Dec 4. PMID: 33277309; PMCID: PMC7933059.